Page last updated: 2024-12-06

2,3,6,2',3',6'-hexachlorobiphenyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2,3,6,2',3',6'-hexachlorobiphenyl (PCB 153) is a highly chlorinated polychlorinated biphenyl (PCB) congener that has been extensively studied due to its environmental persistence, bioaccumulation, and potential toxicity. It is a colorless, odorless solid that is insoluble in water but soluble in organic solvents. PCBs were manufactured and used extensively in industrial applications, such as electrical transformers, capacitors, and hydraulic fluids, from the mid-20th century until their production was largely banned in the 1970s. However, PCBs persist in the environment due to their resistance to degradation. PCB 153, like other PCBs, can enter the environment through spills, leaks, and improper disposal. Once in the environment, PCBs can be transported long distances by air and water, and they can accumulate in the food chain, especially in fatty tissues of animals. PCB 153, along with other PCBs, has been shown to have a variety of adverse effects on human health, including endocrine disruption, immune suppression, neurotoxicity, and cancer. It can also affect the reproductive system and development in animals. Due to these concerns, PCBs are considered persistent organic pollutants (POPs) and are subject to international regulations. There is ongoing research into the environmental fate, transport, and toxicity of PCBs, including PCB 153, to better understand their impacts and develop strategies for their remediation. It is important to note that the synthesis of PCB 153 is complex and typically involves multiple steps. However, the specific details of the synthesis process are often considered proprietary information and may not be publicly available.'

Cross-References

ID SourceID
PubMed CID38024
CHEBI ID34199
SCHEMBL ID2933260
MeSH IDM0056028

Synonyms (21)

Synonym
2,3,6,2',3',6'-hexachlorobiphenyl
2,2',3,3',6,6'-hexachloro-1,1'-biphenyl
CHEBI:34199 ,
2,2',3,3',6,6'-hexachlorobiphenyl
1,1'-biphenyl, 2,2',3,3',6,6'-hexachloro-
inchi=1/c12h4cl6/c13-5-1-3-7(15)11(17)9(5)10-6(14)2-4-8(16)12(10)18/h1-4
brn 2294224
(+-)-pcb 136
2,2', 3,3',6,6'-hexachlorobiphenyl
pcb 136
38411-22-2
1,2,4-trichloro-3-(2,3,6-trichlorophenyl)benzene
moa04j1vtw ,
unii-moa04j1vtw
SCHEMBL2933260
FZFUUSROAHKTTF-UHFFFAOYSA-N
DTXSID6073499 ,
pcb no. 136 10 microg/ml in isooctane
pcb no. 136
Q27115897
dtxcid9039490

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Following the dosing schedule, animals were killed at 1, 5 and 8 days."( In vivo binding of 2,3,6,2',3',6'-hexachlorobiphenyl and 2,4,5,2',4',5'-hexachlorobiphenyl to mouse liver macromolecules.
Matthews, HB; Morales, NM, 1979
)
0.59
" Enantioselective analysis showed that (+)-PCB 136 was enriched in most organs, with the most pronounced enrichment found in the liver and the brain of animals dosed orally or by intraperitoneal injection, respectively."( Enantioselective disposition of PCB 136 (2,2',3,3',6,6'-hexachlorobiphenyl) in C57BL/6 mice after oral and intraperitoneal administration.
Hornbuckle, KC; Kania-Korwel, I; Lehmler, HJ; Robertson, LW; Shaikh, NS, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hexachlorobiphenylAny polychlorobiphenyl with molecular formula C12H4Cl6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (25.93)18.7374
1990's3 (11.11)18.2507
2000's6 (22.22)29.6817
2010's10 (37.04)24.3611
2020's1 (3.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.42 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]